Cargando…

The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease

BACKGROUND: Inflammatory bowel disease (IBD) is associated with poor quality of life and disability. The short inflammatory bowel disease questionnaire (SIBDQ) is validated to determine patients quality of life at single time points, or improvement over time. Few studies have evaluated if sustained...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anderson, Alyce, Click, Benjamin, Ramos-Rivers, Claudia, Koutroubakis, Ioannis E, Hashash, Jana G, Dunn, Michael A, Schwartz, Marc, Swoger, Jason, Barrie, Arthur, Regueiro, Miguel, Binion, David G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	IBD Live
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085986/ https://www.ncbi.nlm.nih.gov/pubmed/29860492 http://dx.doi.org/10.1093/ibd/izy040

Ejemplares similares

2162: The impact of Clostridium difficile infection on disease severity in patients with inflammatory bowel disease
por: Anderson, Alyce J. M., et al.
Publicado: (2018)

Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype
por: Jiang, Jianfei, et al.
Publicado: (2016)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease
por: Han, Lichy, et al.
Publicado: (2018)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases
por: Ghosh, Subrata, et al.
Publicado: (2017)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

Elevated serum globulin fraction as a biomarker of multiyear disease severity in inflammatory bowel disease
por: Hashash, Jana G., et al.
Publicado: (2022)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient–Physician Visits
por: Rubin, David T., et al.
Publicado: (2017)

Risk of dementia in patients with inflammatory bowel disease: a Danish population‐based study
por: Rønnow Sand, Jakob, et al.
Publicado: (2022)

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population‐based cohort study
por: Eriksson, Carl, et al.
Publicado: (2018)

Lymphangiogenesis in Inflammatory Bowel Disease; A New Therapeutic Target?
por: Koutroubakis, Ioannis E, et al.
Publicado: (2016)

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease
por: Darlington, Kimberly, et al.
Publicado: (2023)

Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients
por: Lam, Angela Y., et al.
Publicado: (2020)

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients
por: Kennedy, N A, et al.
Publicado: (2014)

Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population‐based study
por: Jayasooriya, Nishani, et al.
Publicado: (2022)

The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases—an international Delphi consensus survey
por: Madsen, Gorm Roager, et al.
Publicado: (2022)

Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden
por: Druvefors, Emma, et al.
Publicado: (2022)

Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2022)

Going Viral: Management of IBD in the Era of the COVID-19 Pandemic
por: Gutin, Liat S., et al.
Publicado: (2020)

Opportunistic Knocks: A Gardener with Ulcerative Colitis and New Pulmonary Nodules
por: Canakis, Andrew, et al.
Publicado: (2023)

The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method
por: Reinisch, W, et al.
Publicado: (2013)

Barriers to optimizing inflammatory bowel disease care in the United States
por: Spencer, Elizabeth A., et al.
Publicado: (2023)

Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype
por: Broekman, M. M. T. J., et al.
Publicado: (2017)

Active tuberculosis in inflammatory bowel disease patients: a case–control study
por: Freitas Cardoso de Azevedo, Matheus, et al.
Publicado: (2023)

Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients
por: Martins, Camilla de Almeida, et al.
Publicado: (2023)

Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis
por: Prokopič, Michal, et al.
Publicado: (2023)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population‐based, longitudinal study
por: Burgess, Christopher J., et al.
Publicado: (2022)

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
por: Chanchlani, Neil, et al.
Publicado: (2022)

Harnessing Regulatory T Cells for the Treatment of Inflammatory Bowel Disease
por: Geem, Duke, et al.
Publicado: (2015)

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
por: Colombel, J.‐F., et al.
Publicado: (2016)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis
por: Lyons, Mathew, et al.
Publicado: (2022)

Enteric Glial Cells: A New Frontier in Neurogastroenterology and Clinical Target for Inflammatory Bowel Diseases
por: Ochoa-Cortes, Fernando, et al.
Publicado: (2015)

Metagenomic Analysis of Microbiome in Colon Tissue from Subjects with Inflammatory Bowel Diseases Reveals Interplay of Viruses and Bacteria
por: Wang, Weiwei, et al.
Publicado: (2015)

Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study
por: Everhov, Åsa H., et al.
Publicado: (2022)

Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real‐world patient mix
por: Atia, Ohad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t0pjpbhjag181vpvqds47r9qm9